SCHEMBL560697

SCHEMBL560697

Cc1ccc2nc(-c3nc(C(=O)N[C@H](C)c4ccccc4)cnc3N)[nH]c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 8/20 0.48
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45
MMP13 P45452 1/20 0.45
CNR1 P21554 1/20 0.44
BACE1 P56817 3/20 0.43
BACE2 Q9Y5Z0 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPK1 P28482 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CHEK2 O96017 1/20 0.41
PDE2A O00408 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560932 1.00 ATR (0.48) ATRMMP2MMP9MMP8MMP13
SCHEMBL560593 0.85 MMP2 (0.58) ATRMMP2MMP9MMP8MMP13
SCHEMBL560651 0.82 ATR (0.53) ATRMMP2MMP9MMP8MMP13
SCHEMBL559812 0.81 ATR (0.51) ATRMMP2MMP9MMP8MMP13
SCHEMBL560599 0.81 MMP2 (0.61) ATRMMP2MMP9MMP8MMP13
SCHEMBL560937 0.79 ATR (0.55) ATRKDM4EALDH1A1NPC1GAA
SCHEMBL560220 0.79 ATR (0.53) ATRMMP2MMP9MMP8MMP13
SCHEMBL10166538 0.79 ATR (0.57) ATRMMP2MMP9MMP8CNR1
SCHEMBL560124 0.78 ATR (0.52) ATRMMP2MMP9MMP8MMP13
SCHEMBL560074 0.78 ATR (0.52) ATRMMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
EP-2569289-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ATR 1/4885MMP2 4673/4885MMP9 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.